RS7 antibodies

Details RS7 antibodies RS7 antibodies

2007-07-03

2007-07-03

Blanchard, David J. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388220, C530S388800, C530S388850, C530S391300, C530S391700, C424S133100, C424S136100, C424S143100, C424S155100, C424S156100, C424S181100, C435S069600

Reexamination Certificate

active

10377121

ABSTRACT:
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6558669 (2003-05-01), Govindan et al.
patent: 6653104 (2003-11-01), Goldenberg
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 100 34 607 (2002-02-01), None
patent: WO 98/12227 (1998-03-01), None
patent: WO 98/42378 (1998-10-01), None
patent: WO 00/69914 (2000-11-01), None
Morrison et al. Proc. Natl. Acad. Sci., USA 81:6851-6855, Nov. 1984.
Fundamental Immunology, p. 242, William E. Paul, M.D. ed., 3rd ed. 1993.
Stein R. et al. Cancer, 73(3 Suppl):816-823, Feb. 1, 1994.
Basu A. et al. Int. J Cancer. 62(4):472-479, Aug. 9, 1995.
Stein R et al. Cancer Research. 55(14):3132-3139, Jul. 15, 1995.
Shih L. B. et al. Journal Nuclear Medicine. 35(5):899-908, May 1994.
Stein R. et al. Int. J Cancer. 55(6):938-946, Dec. 2, 1993.
Stein R. et al. Int. J Cancer Suppl. 8:98-102, 1994.
Stein R et al. Cancer Research. 50(4):1330-1336, Feb. 15, 1990.
William E. Paul. Fundamental Immunology, pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, 1982.
XP-001154527—Zhengxing Qu et al., “Humanization of IMMU31, An α-Fetoprotein-Specific Antibody1”, Clinical Cancer Research, Oct. 1999, pp. 3095s-3100s , vol. 5, No. 10.
XP-000999121—Lisa B. Shih et al., “In Vitro and In Vivo Reactivity of an Internalizing Antibody, RS7, With Human Breast Cancer”, Cancer Research (Suppl.), Dec. 1995, pp. 5857s-5863s, vol. 55, No. 10.
XP-002207879—Reinhilde Schoonjans et al., “Fab Chains as an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1”, The Journal of Immunology, Dec. 2000, pp. 7050-7057, vol. 165, No. 12.
XP-000616008—S.O. Leung, et al., “Chimeriation of LL2, A Rapidly Internalizing Antibody Specific for B Cell Lymphoma”, Hybridoma, Dec. 1994., pp. 469-476, vol. 13, No. 6.
XP-001154183—Rhona Stein et al., “Therapy of a Breast Cancer Xenograft Using Humanized RS7 Labeled With Residualizing Iodine”, Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2002, vol. 43, pp. 88-89, (Abstract).

Affiliated with

Also associated with

Rating

RS7 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RS7 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RS7 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3720601